T imely reperfusion with primary percutaneous coronary intervention (PCI) is the recommended treatment of patients with ST-segment-elevation myocardial infarction (STEMI). 1,2 Multivessel disease is a frequent observation in
STEMI patients and is related to impaired prognosis, especially in the presence of 3-vessel disease or a chronic total occlusion. 3, 4 The indication for treatment of noninfarct-related lesions is controversial and an issue that has gained increasing attention. Data from the largest meta-analysis, almost entirely based on registry studies, suggest that a strategy of staged complete revascularization improves outcome compared with both complete revascularization performed during the index PCI or PCI of the infarct-related artery only. 5 Prior randomized studies unequivocally indicate a benefit from complete revascularization compared with treatment of the infarctrelated artery only at least with regard to a reduction in the need for new revascularization, whereas there is discrepancy in terms of reducing hard end points of mortality and reinfarction. [6] [7] [8] The PRAMI trial (Preventive Angioplasty in Acute Myocardial Infarction) demonstrated benefits in both hard and soft end points. 6 In the third DANAMI 3-PRIMULTI (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization), staged fractional flow reserve (FFR)-guided complete revascularization reduced ischemiadriven revascularization but not mortality or reinfarction rates compared with PCI of the infarct-related artery only. 7 It is, therefore, uncertain how these results should affect clinical practice, and it is relevant to identify patient subgroups with enhanced benefit from complete revascularization. The severity of multivessel disease varies, the location of the noninfarct-related stenosis can be proximal or more distal, and the disease may involve either 1 (2-vessel disease) or 2 (3-vessel disease) coronary arteries in addition to the infarct related, and these factors represent various extents of ischemic burden that may influence the benefit of complete revascularization on outcome. Thus, the aim of this post hoc substudy to the randomized DANAMI 3-PRIMULTI trial was to evaluate the impact of number of diseased vessels, lesion location, and stenosis severity of the noninfarct-related lesions on the benefits from staged FFR-guided complete revascularization versus conservative treatment in STEMI patients in connection with their culprit PCI.
Methods

Study Design and Population
The present study is a post hoc substudy to the previously published randomized DANAMI 3-PRIMULTI study. 7, 9 Briefly, patients with STEMI and <12 hours from symptom onset that had successful primary PCI of the culprit lesion were included if they had at least 1 additional lesion with a diameter stenosis ≥50% (visually estimated on the initial angiogram) in a noninfarct-related artery with a diameter >2.0 mm. STEMI was defined as >1 mm ST-segment-elevation in at least 2 contiguous leads. The main exclusion criteria were cardiogenic shock, stent thrombosis, significant left main stenosis, indication for coronary artery bypass grafting, increased risk of bleeding, and intolerance to contrast media or anticoagulation medication. The patients were randomized to either no further invasive assessment/ treatment or FFR-guided complete revascularization 2 days after primary PCI (complete revascularization). In the latter group randomized to complete revascularization, a second angiogram was performed, and lesions were considered significant in case of either an FFR value ≤0.80 or a visually assessed diameter stenosis ≥90%.
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The significant noninfarct artery stenoses were treated with PCI unless they were deemed unsuitable for PCI. In that case, coronary artery bypass grafting was considered. The study was performed in accordance with the Declaration of Helsinki. The local ethics committee approved the study, and each patient provided written informed consent.
Patient Subgroups
The patients were stratified according to numbers of affected vessels (2-vessel disease versus 3-vessel disease), location of the noninfarctrelated stenosis (proximal versus distal), and noninfarct artery diameter stenosis (<90% versus ≥90%). We did not consider any other subgroups beyond these 3 and those prespecified in the parent study. Two-vessel disease was defined as culprit lesion plus at least 1 additional stenosis in only 1 noninfarct-related artery and 3-vessel disease as culprit lesion+stenoses in 2 noninfarct-related arteries. In patients with left dominance, coronary anatomy disease in the left anterior descending artery territory and proximal part of the left circumflex was considered 3-vessel disease. The patients were divided according to the presence of at least 1 lesion with diameter stenosis ≥90%. This cutoff value was chosen because practically all coronary lesions ≥90% diameter stenosis are functionally significant, when assessed with FFR in a population of stable ischemic heart disease. 10 In case of multiple noninfarct-related stenoses ≥50%, the most severe stenosis was reported. Proximal noninfarct-related stenosis was defined as a lesion ≥50% diameter stenosis located in the left main or in the proximal part of left anterior descending artery, right coronary artery, or left circumflex. The physician performing the PCI reported the diameter stenosis, lesion location, and numbers of affected vessels immediately after the index procedure.
Study End Points
The primary end point was a composite of all-cause mortality, reinfarction, or ischemia-driven revascularization. As in the original study, secondary end points were the individual components of the primary end point. Ischemia-driven revascularization was defined
WHAT IS KNOWN
• Complete revascularization improves the outcome compared with only treating the infarct-related artery in patients with ST-segment-elevation myocardial infarction and multivessel disease; however, the clinical impact of disease severity in these patients is uncertain.
WHAT THE STUDY ADDS
• This substudy of the DANAMI 3-PRIMULTI trial (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization) demonstrated that the benefit from staged fractional flow reserve-guided complete revascularization compared with infarct artery percutaneous coronary intervention in ST-segment-elevation myocardial infarction was observed primarily in patients with both 3-vessel disease and at least 1 noninfarct-related stenosis with diameter ≥90%.
• These findings, thus, help to identify a high-risk population in whom fractional flow reserve-guided complete revascularization should be considered, whereas it appears safe to waive revascularization in the patients who do not meet these criteria.
as any revascularization of lesions in noninfarct-related arteries performed on the basis of either angina pectoris or a positive noninvasive ischemia test. Urgent revascularization was defined as revascularization during admission for acute coronary syndrome.
Statistical Analysis
All analyses were performed on an intention-to-treat basis. The impact of number of diseased vessels (2-versus 3-vessel disease), location of the noninfarct-related stenosis (proximally versus distally) Data are presented as mean±SD, median (interquartile range), or n (%) unless otherwise indicated. ACE indicates angiotensin-converting-enzyme; ARB, angiotensin II-receptor blocker; FFR, fractional flow reserve; and PCI, percutaneous coronary intervention.
*P value for a trend between any of the patient groups calculated by the appropriate multidegree of freedom test. †In the post hoc, the statistically significant difference was observed between 2-and 3-vessel disease but not between treatment groups. ‡In the post hoc, the statistically significant difference was observed between 2-and 3-vessel disease and between treatment groups. §There was no statistical significant difference in the post hoc analysis when adjusting for multiple testing.
and severity of the noninfarct-related artery stenosis (<90% versus ≥90%) on the effect of complete revascularization versus culprit-only treatment was evaluated. Data are presented by their mean (±standard deviation), median (interquartile range), or number (%). Comparison between groups was performed using 1-way analysis of variance, Kruskal-Wallis equality-of-populations rank test, or χ2 test. Post hoc analyses were performed using the Mann-Whitney U test and χ2 test, and the P value was adjusted for multiple comparisons by multiplying the calculated P value with 6. Kaplan-Meier curves were used for visual assessment of time-to-event end points that included mortality and Log rank for statistical comparison. Hazard ratios were calculated by Cox regression analysis. Interaction between the patient groups and treatment allocation (infarct-related artery only versus FFR-guided complete revascularization) was performed in a Cox model, including the interaction variable. In case >1 angiography characteristic had significant impact on the outcome after FFR-guided complete revascularization, interaction between these characteristics and the treatment allocation was assessed in a Cox model. A P value <0.05 was considered significant. All analysis was done using SPSS (version 22, SPSS Inc, Chicago, IL).
Results
Baseline Characteristics, Angiography-Related Data, and Treatment
Between March 2011 and February 2014, 627 patients were randomized. 7 On the initial angiogram, 197 patients (31%) had 3-vessel disease, 176 (28%) had at least 1 noninfarctrelated stenosis located in the proximal part of a main coronary artery or in the left main, and 202 (32%) had at least 1 noninfarct-related lesion with a diameter stenosis ≥90%. Table 1 shows the patients' baseline variables, PCI characteristics, and discharge medication according to treatment allocation and numbers of diseased vessels. The baseline variables, PCI characteristics, and medication according to noninfarct diameter stenosis are shown in Table I in the Data Supplement.
A total of 193 (61%) of the patients randomized to FFRguided complete revascularization had PCI or coronary artery bypass surgery of a noninfarct-related artery. Of these 193 patients, 183 (58%) had revascularization with PCI during the index admission, 3 (1%) underwent coronary artery bypass surgery, and 97 (31%) had FFR value >0.80 in the noninfarctrelated stenosis; thus, 283 (90%) patients were considered as completely revascularized during the index admission. Additional 10 patients underwent FFR-guided revascularization after discharge, of whom 4 were treated with PCI, 3 with coronary artery bypass surgery, and 3 had FFR value >0.80 in the noninfarct-related stenosis. Twenty patients, planned for complete revascularization during initial admission or after discharge, had incomplete revascularization because of failed procedure/unsuitable lesion (15), death before revascularization (1), refusal (2), or other reasons (2) . The number of patients' actual receiving revascularization is shown in Table  II in the Data Supplement, and the distribution of patients according to FFR-positive lesions and diameter stenosis ≥90% is shown in Table III in the Data Supplement.
Outcome According to Angiographic Findings
During a median follow-up of 23 months (range 7-45), a total of 108 (17%) patients met the primary composite end point. One patient emigrated after 7 months, but all other patients were followed throughout the follow-up period of minimum 1 year. The event rate, hazard ratio, and corresponding P value for the primary end point are shown in Table 2 . Among patients with 3-vessel disease, FFR-guided complete revascularization resulted in a marked reduction in the primary end point compared with infarct-related artery revascularization only, whereas there was no significant difference in the primary end point between the 2 treatment groups for patients with 2-vessel disease (Table 2 and Figure 1 ). There was statistically significant interaction between the number of diseased vessels and the allocated treatment effect ( Table 2 ). The benefit from complete revascularization among patients with 3-vessels disease was driven by ischemia-driven revascularization (Table II in the Data Supplement). The treatment effect was also related to the severity of the diameter stenosis in the noninfarct-related arteries (Table 2) . FFR-guided complete revascularization reduced the primary end point to a greater extent in patients with at least 1 noninfarct-related lesion of ≥90% compared with patients with <90% diameter stenosis (Table 2 and Figure 2 ). The benefit from complete revascularization among patients with ≥90% diameter stenosis was also driven by ischemia-driven revascularization (Table III in the Data Supplement). Among patients with high-grade stenoses randomized to complete revascularization, 15 patients had incomplete revascularization. In an as-treated analysis, the hazard ratio of the primary composite end point was 0.47 (95% confidence interval, 0.25-0.88;
P=0.018).
There was no significant interaction between FFR-guided complete revascularization and proximal noninfarct-related lesion (P for interaction 0.59). Thus, FFR-guided complete revascularization reduced the primary end point both in patients with proximal (hazard ratio, 0.45; 95% confidence interval, 0.19-1.05; P=0.07) and distal noninfarct-related lesions (hazard ratio, 0.60; 95% confidence interval, 0.39-0.93; P=0.023).
There was statistically significant 3-way interaction between treatment allocation (FFR-guided complete revascularization versus infarct-related artery only), number of diseased vessels (2-versus 3-vessel disease), and severity of the noninfarct stenosis (<90% versus ≥90%; P for interaction 0.015). Based on these findings, patients were divided into the following 4 groups: (1) 2-vessel disease and noninfarctrelated diameter stenosis <90%; (2) 2-vessel disease and at least 1 noninfarct-related stenosis ≥90%; (3) 3-vessel disease and noninfarct-related diameter stenosis <90%, and (4) 3-vessel disease and at least 1 noninfarct-related stenosis ≥90% (Table 2 ). In patients with 3-vessel disease and at least 1 noninfarct-related stenosis ≥90%, FFR-guided complete revascularization resulted in a substantial reduction in the primary end point with significant 2-way interaction (P for interaction 0.019) between the 4 patient groups and randomization (Table 2 and Figure 3 ). Evaluating the individual components of the primary end point as well as other prespecified secondary end points for this patient group, all end points had low hazard ratios favoring FFR-guided complete revascularization (Table 3) . However, there was only statistically significant difference in terms of ischemia-driven revascularization, but numerically reduction in all other end points after FFR-guided complete revascularization (Table 3) .
Discussion
Results from this substudy of the randomized DANAMI 3-PRIMULTI trial demonstrate that the benefit from staged FFR-guided complete revascularization compared with infarctrelated PCI only in STEMI patients depends on the presence of 3-vessel disease and at least 1 noninfarct-related lesion with diameter stenosis ≥90%. In patients with both 3-vessel disease and at least 1 noninfarct-related stenosis with diameter ≥90%, FFR-guided complete revascularization reduced the incidence of the primary composite end point of mortality, reinfarction, and ischemia-driven revascularization significantly from 41% to 8% (relative reduction 76%) and the combination of mortality and reinfarction nonsignificantly from 16% to 6%. These patients represent a high-risk population in whom FFR-guided complete revascularization should be considered, whereas it seems safe to waive revascularization in the patients who do not meet these criteria. Future prospective trials should confirm these findings.
In the DANAMI 3-PRIMULTI main study, FFR-guided complete revascularization resulted in a significant reduction in the primary composite end point, driven by a reduction in revascularization. 7 It has been uncertain how these findings should be incorporated into clinical practice because a strategy of FFR-guided complete revascularization in all STEMI patients with multivessel disease leads to more invasive procedures and stent implantations, which might imply an increased risk of complications (such as stent thrombosis), as well as economical costs. 13 Findings in the present study are, therefore, clinically important because they identify a patient subgroup in which complete revascularization may reduce the incidence of the composite hard end point of death and reinfarction. Moreover, these findings may help to select the proper patients with STEMI and multivessel disease for complete FFR-guided revascularization and waived revascularization, respectively. This initial risk assessment can be done immediately after the initial procedure by visual assessment of the angiogram without the need for additional invasive procedures. The primary composite end point according to randomization group for patients with 3-vessel disease and ≥90% noninfarct-related stenosis. Kaplan-Meier curves for patients with at least 1 noninfarct-related stenosis >90% and 3-vessel disease treated with infarctrelated artery only percutaneous coronary intervention or fractional flow reserve (FFR)-guided complete revascularization. Primary composite end point, all-cause death, reinfarction, and ischemia-driven revascularization.
In the PRAMI trial, complete revascularization reduced the primary composite end point of cardiac death, reinfarction, and refractory angina by 65%, a treatment effect that was observed across all individual components of the primary end point. 6 In addition, the CvLPRIT trial (Complete Versus Lesion-Only Primary PCI) found a 55% relative reduction in the primary composite end point of all-cause mortality, recurrent infarction, heart failure, and revascularization with a numeric but not statistically significant reduction in all individual end points after complete revascularization. 8 Opposed to these findings, the treatment effect in the DANAMI 3-PRIMULTI trial was not reflected in differences in mortality and reinfarction, which is in accordance with the PRAGUE-13 trial (unpublished). The difference between clinical outcomes in these studies could potentially be explained by the timing of complete revascularization, performed during the index procedure in all patients in the PRAMI trial and in 64% of the patients in the CvLPRIT compared with the staged strategy in the DANAMI 3-PRIMULTI and PRAGUE-13. However, in a previous randomized trial, immediate complete PCI did not reduce the event rates compared with a staged complete PCI strategy, 14 and the majority of events occurred after complete revascularization in DANAMI 3-PRIMULTI. Another explanation for the different findings could be the use of FFR in DANAMI 3-PRIMULTI, which resulted in 31% of the patients in the complete revascularization group did not undergo further revascularization. 7 However, there is no overall difference in the FFR value in nonculprit lesion when measured acutely compared with at follow-up 1 month after the index PCI. 15 Nevertheless, it could be speculated that the FFR-negative lesions were unstable and that acute treatment of these lesions in PRAMI and CVLPRIT reduced the event rate. However, it is also important to emphasize the higher event rate in the control group in the PRAMI trial compared with the DANAMI 3-PRIMULTI trial (reinfarction 9% versus 5% and all-cause death 7% versus 4%), which indicates that the study population in PRAMI and DANAMI 3-PRIMULTI are different in terms of risk for suffering death and reinfarction. In this regard, the rates of all-cause mortality and reinfarction in the present study in patients with 3-vessel disease and at least 1 noninfarct-related lesion with diameter stenosis ≥90% treated with infarct-related revascularization only were similar to those in the control group in the PRAMI trial (reinfarction 9% versus 8% and all-cause mortality 7% versus 8%). Moreover, 465 patients were included during 5 years at 5 centers in the PRAMI trial corresponding to 19 patients per year per center. In contrast, we included 627 patients during 3 years at 2 centers corresponding to 105 patients per year per center in the DANAMI 3-PRIMULTI. Thus, we find it likely that the difference in effect of complete revascularization on all-cause death and reinfarction between these 2 studies is caused by a more pronounced effect of complete revascularization in patients with worse disease, which is complete in line with results of our subgroup analysis. Nonetheless, the optimal strategy for treatment of noninfarct-related stenosis in STEMI patients with multivessel disease remains uncertain, and forthcoming large randomized studies will hopefully shed further light on this issue.
Findings in the present study was not surprising because the outcome after revascularization in patients with stable coronary artery disease depends on the presence of inducible ischemia assessed by FFR, 11, 12, 16, 17 and almost all coronary lesions >90% stenosis seem to be functionally significant when assessed with FFR. 10 Moreover, patients with 3-vessel disease were more likely to have a lesion with diameter stenosis ≥90%, more extensive coronary artery disease, and, thus, larger plaque burden, all predictors of cardiac events in patients with acute coronary syndrome. 18 In line with this, among the patients treated with infarct-related artery-only PCI, the event rate was 41% in patients with 3-vessel disease and at least 1 noninfarct-related lesion ≥90% compared with 16% to 22% in the remaining patients. However, the event rate in the patients treated with FFR-guided complete revascularization seemed to be smaller among patients with 3-vessel disease and at least 1 noninfarct-related lesion ≥90% (8% versus 11%-18%), indicating that some of the treatment effect may be attributed to a higher rate of revascularization per se. It is unclear whether the functional significance of stenosis in noninfarctrelated arteries in STEMI patients is of the same magnitude as in stable patients because of the disturbed microcirculation in patients with STEMI. However, according to Ntalianis et al, 15 measurement of FFR in the noninfarct-related arteries seems to be a much smaller problem than anticipated. Moreover, FFR measurements in the present study were deferred for >48 hours. In the present study, 32% of the patients had at least 1 noninfarct-related lesion with diameter stenosis ≥90 compared with 15% in a cohort of patients with stable coronary artery disease. 10 It is known that a diameter stenosis is often overestimated when assessed visually rather than by quantitative coronary angiography, which in part may explain the relatively high prevalence of severe diameter stenoses. Because previous otherwise comparable studies have involved patients without STEMI, new scientific data to support clinical decision making in these patients are warranted.
According to the trial protocol FFR was not mandatory in lesions with diameter stenosis ≥90%, which may question the need for FFR guidance in this particular setting. However, patients with at least one stenosis ≥90% could still have other lesions with diameter stenosis <90% that needed FFR-guided PCI, especially in patients with coexisting 3-vessel disease. Thus, FFR still has an important role in the decision of revascularization STEMI patients with multivessel disease.
That complete revascularization prevents reinfarction as observed in the PRAMI and CvLPRIT trials, and in our highrisk patients, concur with the fact that in patients with acute coronary syndrome undergoing PCI, reinfarction frequently occur in coronary lesions <50% diameter stenosis. [18] [19] [20] In the PROSPECT trial (An Imaging Study in Patients With Unstable Atherosclerotic Lesions), 67% of the coronary lesions that led to a major cardiac event had a diameter stenosis <50% on the initial coronary angiography, and only 5% had a diameter stenosis >70%. However, the minority of patients in the PROSPECT trial had STEMI (30%) and 27% had PCI in >1 vessel before inclusion. 18 Other important differences between earlier and contemporary trials are the medical regimens, including both antiplatelet and statin treatment. 21 This trial has some limitations. Being a post hoc study, the findings should be confirmed in a prospective trial. Nevertheless, we find the subgroup analyses in the present article credible because they were derived from an original study with a positive primary end point. Given the many statistical comparisons and relative few patients in the subgroups, the occurrence of type I and II errors cannot be ruled out. Moreover, the results regarding the hard end points did only show a trend toward a reduction owing to the small numbers of hard end points in the subgroups. In addition, visually determined stenosis severity can vary considerably, and the use of quantitative coronary angiography would have given more precise results. On the other hand, the present study is based on diameter stenoses assessed in the acute setting by the operator and, thus, reflects clinical practice in most institutes.
Owing to the protocol, FFR values were not performed in the majority of lesions with diameter stenosis >90%. Finally, the patients were told that they had additional coronary artery disease, whereas the extent and severity of the nonculprit coronary artery disease were not explained to them. In addition, physicians referring the patients for subsequent revascularization were allowed access to the initial angiographic report, which may have influenced their assessment of the patients' symptoms and need for additional revascularization.
In conclusion, in the present DANAMI 3-PRIMULTI substudy, the clinical benefit from FFR-guided complete revascularization in STEMI patients with multivessel disease was dependent on the presence of 3-vessel disease and a noninfarct-related coronary stenosis ≥90%. In particular, complete revascularization reduced the primary end point substantially in patients with 3-vessel disease and diameter stenoses ≥90%. 
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